{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:12:37Z","timestamp":1779174757881,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"DOI":"10.7759\/cureus.109160","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:46:11Z","timestamp":1779173171000},"source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Pathological Complete Response and Patient-Reported Outcomes During Neoadjuvant Chemotherapy in Early Breast Cancer: A Single-Center Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Isabela Anda","family":"Komporaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelina Silvana","family":"Gheorghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena Adriana","family":"Iovanescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia Anca","family":"Kajanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Georgescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Stanculeanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5894","article-title":"Neoadjuvant chemotherapy for operable breast cancer","volume":"94","author":"Mieog JS","year":"2007","unstructured":"Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007, 94:1189-200. 10.1002\/bjs.5894","journal-title":"Br J Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2108-2","article-title":"Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer","volume":"19","author":"Kaufmann M","year":"2012","unstructured":"Kaufmann M, von Minckwitz G, Mamounas EP, et al.. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012, 19:1508-16. 10.1245\/s10434-011-2108-2","journal-title":"Ann Surg Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109587","article-title":"Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: a population-based study","volume":"51","author":"Liu X","year":"2025","unstructured":"Liu X, Bergman LE, Boman C, Foukakis T, Matikas A. Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: a population-based study. Eur J Surg Oncol. 2025, 51:10.1016\/j.ejso.2025.109587","journal-title":"Eur J Surg Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar P","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al.. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014, 384:164-72. 10.1016\/S0140-6736(13)62422-8","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4404-8","article-title":"Pathological complete response in neoadjuvant treatment of breast cancer","volume":"22","author":"Cortazar P","year":"2015","unstructured":"Cortazar P, Geyer CE Jr. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015, 22:1441-6. 10.1245\/s10434-015-4404-8","journal-title":"Ann Surg Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e43069","article-title":"Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: a systematic review and meta-analysis of real-world data","volume":"11","author":"Antonini M","year":"2025","unstructured":"Antonini M, Mattar A, Pereira TM, et al.. Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: a systematic review and meta-analysis of real-world data. Heliyon. 2025, 11:10.1016\/j.heliyon.2025.e43069","journal-title":"Heliyon"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz G","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, et al.. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012, 30:1796-804. 10.1200\/JCO.2011.38.8595","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring LM","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al.. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020, 26:2838-48. 10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami N","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012, 48:3342-54. 10.1016\/j.ejca.2012.05.023","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023","volume":"34","author":"Curigliano G","year":"2023","unstructured":"Curigliano G, Burstein HJ, Gnant M, et al.. Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol. 2023, 34:970-86. 10.1016\/j.annonc.2023.08.017","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado R","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, et al.. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015, 26:259-71. 10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert C","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, et al.. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018, 19:40-50. 10.1016\/S1470-2045(17)30904-X","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson NK","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al.. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993, 85:365-76. 10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond AS","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983, 67:361-70. 10.1111\/j.1600-0447.1983.tb09716.x","journal-title":"Acta Psychiatr Scand"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4464","article-title":"One in two cancer patients is significantly distressed: prevalence and indicators of distress","volume":"27","author":"Mehnert A","year":"2018","unstructured":"Mehnert A, Hartung TJ, Friedrich M, et al.. One in two cancer patients is significantly distressed: prevalence and indicators of distress. Psychooncology. 2018, 27:75-82. 10.1002\/pon.4464","journal-title":"Psychooncology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(01)00296-3","article-title":"The validity of the hospital anxiety and depression scale: an updated literature review","volume":"52","author":"Bjelland I","year":"2002","unstructured":"Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res. 2002, 52:69-77. 10.1016\/S0022-3999(01)00296-3","journal-title":"J Psychosom Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin MB","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al.. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging. CA Cancer J Clin. 2017, 67:93-9. 10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans WF","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, et al.. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007, 25:4414-22. 10.1200\/JCO.2007.10.6823","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-29","article-title":"The Hospital Anxiety and Depression Scale","volume":"1","author":"Snaith RP","year":"2003","unstructured":"Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes. 2003, 1:10.1186\/1477-7525-1-29","journal-title":"Health Qual Life Outcomes"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba D","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998, 16:139-44. 10.1200\/JCO.1998.16.1.139","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell FE Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996, 15:361-87. 10.1002\/(SICI)1097-0258(19960229)15:4&lt;361::AID-SIM168&gt;3.0.CO;2-4","journal-title":"Stat Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/03610928008827941","article-title":"Goodness of fit tests for the multiple logistic regression model","volume":"9","author":"Hosmer DW","year":"1980","unstructured":"Hosmer DW, Lemeshow S. Goodness of fit tests for the multiple logistic regression model. Commun Stat Theory Methods. 1980, 9:1043-69. 10.1080\/03610928008827941","journal-title":"Commun Stat Theory Methods"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi S","year":"2019","unstructured":"Loi S, Drubay D, Adams S, et al.. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019, 37:559-69. 10.1200\/JCO.18.01010","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al.. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020, 382:810-21. 10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf EA","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, et al.. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020, 396:1090-100. 10.1016\/S0140-6736(20)31953-X","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl S","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al.. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024, 35:159-82. 10.1016\/j.annonc.2023.11.016","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans WF","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, et al.. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017, 35:1049-60. 10.1200\/JCO.2015.63.1010","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan H","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, et al.. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017, 377:1836-46. 10.1056\/NEJMoa1701830","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab202","article-title":"The incidence of breast cancer recurrence 10-32 years after primary diagnosis","volume":"114","author":"Pedersen RN","year":"2022","unstructured":"Pedersen RN, Esen B\u00d6, Mellemkj\u00e6r L, et al.. The incidence of breast cancer recurrence 10-32 years after primary diagnosis. J Natl Cancer Inst. 2022, 114:391-9. 10.1093\/jnci\/djab202","journal-title":"J Natl Cancer Inst"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2008.01.005","article-title":"Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women","volume":"12","author":"Browall M","year":"2008","unstructured":"Browall M, Ahlberg K, Karlsson P, Danielson E, Persson LO, Gaston-Johansson F. Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs. 2008, 12:180-9. 10.1016\/j.ejon.2008.01.005","journal-title":"Eur J Oncol Nurs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0b013e3181f662ce","article-title":"Health-related quality of life in survivors with breast cancer 1 year after diagnosis compared with the general population: a prospective cohort study","volume":"253","author":"Lee ES","year":"2011","unstructured":"Lee ES, Lee MK, Kim SH, et al.. Health-related quality of life in survivors with breast cancer 1 year after diagnosis compared with the general population: a prospective cohort study. Ann Surg. 2011, 253:101-8. 10.1097\/sla.0b013e3181f662ce","journal-title":"Ann Surg"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.11.004","article-title":"Depression in cancer: the many biobehavioral pathways driving tumor progression","volume":"52","author":"Bortolato B","year":"2017","unstructured":"Bortolato B, Hyphantis TN, Valpione S, et al.. Depression in cancer: the many biobehavioral pathways driving tumor progression. Cancer Treat Rev. 2017, 52:58-70. 10.1016\/j.ctrv.2016.11.004","journal-title":"Cancer Treat Rev"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9357","article-title":"Host factors and cancer progression: biobehavioral signaling pathways and interventions","volume":"28","author":"Lutgendorf SK","year":"2010","unstructured":"Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol. 2010, 28:4094-9. 10.1200\/JCO.2009.26.9357","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00293","article-title":"Management of anxiety and depression in adult survivors of cancer: ASCO Guideline update","volume":"41","author":"Andersen BL","year":"2023","unstructured":"Andersen BL, Lacchetti C, Ashing K, et al.. Management of anxiety and depression in adult survivors of cancer: ASCO Guideline update. J Clin Oncol. 2023, 41:3426-53. 10.1200\/JCO.23.00293","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3747\/co.20.1302","article-title":"A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue","volume":"20","author":"Howell D","year":"2013","unstructured":"Howell D, Keller-Olaman S, Oliver TK, et al.. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue. Curr Oncol. 2013, 20:233-46. 10.3747\/co.20.1302","journal-title":"Curr Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/475441-predictors-of-pathological-complete-response-and-patient-reported-outcomes-during-neoadjuvant-chemotherapy-in-early-breast-cancer-a-single-center-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:46:12Z","timestamp":1779173172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/475441-predictors-of-pathological-complete-response-and-patient-reported-outcomes-during-neoadjuvant-chemotherapy-in-early-breast-cancer-a-single-center-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.109160","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}